Endometrial cancer survivors are the second largest group of female cancer survivors in the United States, estimated at 606 910 women in 2012 (1). The 5-year survival rate for endometrial cancer is 83% but varies by disease stage and grade (1-2). Higher body mass index (BMI) and inactivity are established risk factors for endometrial cancer incidence (2, 3) , although less is known about these factors and survival (4) . A growing body of literature on cancer survival suggests higher overall and cancer-specific mortality for overweight/obese and physically inactive breast and colon cancer survivors (5) . A recent study of Surveillance, Epidemiology and End Results (SEER) data with 33 232 endometrial cancer patients who died found that the most common cause of 5-year mortality was death due to endometrial cancer, whereas at 10 years and later intervals, death due to cardiovascular disease (CVD) was most common (6) .
A recent systemic review of 12 studies of BMI and endometrial cancer survival (7) was inconclusive: Some studies reported an increased risk of all-cause mortality with higher BMI (8) (9) (10) (11) , whereas other studies showed no association (12) (13) (14) (15) (16) (17) (18) (19) . Of four studies with information on BMI and disease-specific mortality, three found no association (8, 10, 13 ) and a fourth reported more endometrial cancer deaths among morbidly obese women (11) . An additional recent study in the Women's Health Initiative (WHI) found an association between BMI and overall and diseasespecific mortality among endometrial cancer survivors (20) . These inconsistent findings on BMI and mortality among endometrial cancer patients may be explained by small sample sizes, population differences across studies, choice of BMI categorization, time points of BMI measurement in relation to diagnosis, and an inability to adjust for cancer treatment. The WHI study is the only other study on physical activity and mortality among women with endometrial cancer, and it showed no association (20) .
We assessed the associations among prediagnosis BMI and physical activity independently and jointly on total and common causes of mortality among endometrial cancer patients in the National Institutes of Health (NIH)-AARP (formerly known as the American Association of Retired Persons) Diet and Health Study Cohort.
Methods

Study Population
The NIH-AARP Diet and Health Study has been previously described (21) . Briefly, the NIH-AARP cohort included 566 399 AARP members (aged 50-71 years) who completed a mailed baseline questionnaire in 1995-1996. Participants resided in six states (California, Florida, Pennsylvania, New Jersey, North Carolina, or Louisiana) or two metropolitan areas (Atlanta, Georgia; or Detroit, Michigan). Of the 226 732 women who completed baseline questionnaires, we excluded women whose questionnaires were completed by proxy, those diagnosed with cancer before study entry, those with self-reported poor health or end-stage renal disease at baseline, those whose cancer was identified on death certificate only, and those who reported a hysterectomy or had missing information on hysterectomy at baseline. After exclusions, 197 128 women were followed for endometrial cancer. In 1996-1997, an additional risk factor questionnaire was administered that queried in greater detail about physical activity (response rate = 67%). The NIH-AARP Diet and Health study was approved by the Special Studies Institutional Review Board of the US National Cancer Institute, and all participants gave informed consent by virtue of completing and returning the questionnaire.
Cancer Incidence
Cancer case subjects were identified by linkage to the cancer registries of the eight states originally included in the study and to three additional states (Texas, Arizona, and Nevada) to capture cancer among participants who relocated during follow-up. Cancer registry incidence data is estimated to be about 90% complete (22) . Information on date of cancer diagnosis, histology, stage, grade, and first course of treatment reported within 1 year of diagnosis was also gathered from registries. The American Joint Committee on Cancer Staging System was used.
We classified invasive epithelial endometrial carcinoma case subjects using histology codes from the International Classification of Diseases for Oncology, Third Edition, (ICD-O-3 code 54). Among 1466 incident invasive endometrial cancer case subjects identified, we excluded women who reported stopped menstruation due to radiation/chemotherapy (n = 1) or surgery (n = 13), women missing height or weight (n = 37) measurements, and women with BMI less than 18.5 kg/m 2 (n = 15). Thus, a total of 1400 endometrial cancer case subjects were available for the BMI analysis. Among these women, 886 also completed the secondary risk factor questionnaire. We excluded women missing information on physical activity (n = 11), leaving 875 case subjects for the physical activity analysis.
Mortality Ascertainment
Participants were followed for address changes using the US Postal Service's National Change of Address database, and vital status was ascertained annually by linkage to the Social Security Administration Death Master File through December 31, 2009 (all-cause mortality), and the National Death Index Plus through December 31, 2008 (cause-specific mortality). We used ICD-9 and ICD-10 codes to separately classify deaths due to CVD (IDC-9 codes 390-398, 401-404, 410-438, 440-448 and ICD-10 codes I00-I13, I20-I51, I60-I69, and I70-I78) and endometrial cancer (ICD-9 codes 179 and 182, and ICD-10 codes C54-C55).
Exposure Assessment BMI was calculated as kilograms per meter squared using baseline self-reported height and weight. The baseline questionnaire also queried about demographic characteristics, diet, reproductive and medical history, and lifestyles factors. The subsequent risk factor questionnaire assessed leisure time moderate-to-vigorous-intensity physical activities (MVPAs) performed in the last 10 years. Example activities included tennis, golf, biking, swimming, heavy gardening, fast walking or dancing, aerobics, and jogging. Participants reported categorical duration of activities (never, rarely, <1 hour/ week, 1-3 hours/week, 4-7 hours/week, and >7 hours/week). The NIH-AARP physical activity questionnaire has not been validated directly, but it has demonstrated expected inverse associations with risk for colon and endometrial cancer in this cohort (3, 23) .
Statistical Analysis
Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox proportional hazards models in SAS version 9.2 (SAS Institute, Cary, NC). To adjust for age in the best possible way, we used age as the underlying time metric (age at diagnosis and age at death or censoring). This is considered to be a better approach for survival than calendar year because it compares women of similar age (eg, similar comorbidities) over a defined period of time. The proportional hazards assumption, which was evaluated by modeling interaction terms of the continuous main exposure with follow-up time for each model, was met. Follow-up started at endometrial cancer diagnosis and ended at death or end of follow-up, whichever occurred first. For cause-specific death outcomes, deaths from causes other than the one of interest were treated as censoring events. BMI was categorized into predefined groups according to World Health Organization classifications of normal weight (18.5 (24) . Tests for linear trend in BMI models were performed with BMI categories coded in an ordinal fashion. Physical activity was categorized into never/rarely (reference), less than 1 hour/week, 1 to 3 hours/ week, 4 to 7 hours/week, and more than 7 hours/week.
Because BMI was recorded at baseline and time from baseline to diagnosis (lag time) varied, we examined whether hazard ratios for BMI and survival differed by lag time, categorizing women into three time blocks for year at diagnosis (1995-1998, 1999-2002, and 2003-2006) and testing for interaction across four levels of BMI (Supplementary Table 1 , available online). These test results indicated no heterogeneity for 5-year mortality models (P interaction = .15) and borderline nonsignificant heterogeneity for 10-year models (P interaction = .06).
We first built a parsimonious model adjusted for tumor characteristics and treatment using categorical variables for stage (localized, regional, distant), grade (well, moderately, poorly differentiated), surgery (yes/no), and chemotherapy (yes/no). Missing data were treated as separate categories for relevant variables. We explored all variables in Table 1 as confounders and retained factors that changed modeled estimates by more than 10% or that statistically significantly improved model fit as assessed by the likelihood ratio test. We also included race because previous research has shown black women to have poorer survival independent of comorbidities such as diabetes (25) . Thus the final model included further adjustment for race (non-Hispanic white, non-Hispanic black, other), smoking (never, former, current), family history of breast cancer (yes/no), and diabetes (yes/no). Physical activity models were adjusted for the same covariables and are presented with and without adjustment for BMI to address the possibility that BMI is in the causal pathway between physical activity and mortality.
In exploratory analyses, we stratified by stage, grade, and smoking status and created models restricted to type 1 endometrial cancers (n = 1251). Type 1 cases included endometrioid, mucinous, tubular, adenocarcinoma not otherwise specified, and adenocarcinoma with squamous differentiation (ICD codes 8380, 8382, 8383, 8480, 8481, 8482, 8210, 8140, 8560, and 8570). With only 108 type 2 tumors and 36 deaths (defined in Supplementary Methods, available online), we were unable to examine associations between BMI and mortality among these women. All statistical tests were twosided, with P values less than .05 considered statistically significant.
results
Our cohort consisted of 1400 women diagnosed with invasive epithelial endometrial cancer who were diagnosed a median of 5.1 years (range = 0-10.9) after baseline. We identified 312 total deaths through 2009. Cause-specific data through 2008 was used to identify top causes of death among these women: 133 deaths were due to endometrial cancer and 52 deaths were due to CVD. Median BMI at baseline was 28.9 kg/m 2 (range = 18.6-60.1). Baseline characteristics by BMI category are presented in Table 1 . Women with a higher BMI had fewer poorly differentiated tumors, less education, earlier age at menarche, and higher prevalence of diabetes, and they were less likely to use menopausal hormone therapy or oral contraceptives or to smoke.
Prediagnosis BMI was associated with a higher risk of all-cause 5-year mortality. Compared with normal weight women (BMI 18.5 to <25 kg/m 2 ), women who were overweight (BMI 25 to <30) before cancer diagnosis had a 1.74 (95% CI = 1.13 to 2.66) times increased risk of all-cause 5-year mortality, women who were obese (BMI 30 to <35) before cancer diagnosis had a 1.84 (95% CI = 1.17 to 2.88) times increased risk of all-cause 5-year mortality, and women who were very obese (BMI ≥35) before cancer diagnosis had a 2.35 (95% CI = 1.48 to 3.73) times increased risk of all-cause 5-year mortality (Table 2) . Similar results were observed when we restricted the analysis to type 1 endometrial cancer case subjects (HR very obese vs normal weight = 2.43, 95% CI = 1.45 to 4.05), to women without diabetes (HR very obese vs normal weight = 2.74, 95% CI = 1.69 to 4.43), and to women who had never used menopausal hormone therapy (HR very obese vs normal weight = 2.59, 95% CI = 1.31 to 5.10). Additional analyses of BMI and mortality stratified by tumor stage and grade did not indicate effect modification by those factors (Supplementary Table 2 , available online). Sensitivity analyses to examine the impact of missing stage (Supplementary Table 3 , available online) and missing chemotherapy information (data not shown) suggested that the estimates of the associations between BMI and mortality were not strongly affected by missing patterns of those two variables. Although the interaction between BMI and smoking was not statistically significant for all-cause mortality (P interaction = .39), we observed a stronger association among never smokers than in former or current smokers Table 4 , available online). Compared with normal weight women, the hazard ratios for very obese women were 4.39 (95% CI = 2.00 to 9.62) among never smokers, 1.83 (95% CI = 0.90 to 3.74) among former smokers, and 2.18 (95% CI = 0.43 to 11.01) among current smokers. High BMI was also associated with increased risk of 5-and 10-year disease-specific mortality (Table 2) . Compared with normal weight women, very obese women had a statistically significant increased risk of endometrial cancer death within 5 years (HR = 2.39, 95% CI = 1.24 to 4.63; P = .01) and 10 years (HR = 1.79, 95% CI = 1.00 to 3.21; P = .05). Very obese women had a non-significantly elevated risk of CVD death after 5 years (HR = 2.78, 95% CI = 0.78 to 9.84), but they had a more than fourfold statistically significant increased risk of CVD death 10 years after diagnosis (HR = 4.08, 95% CI = 1.56 to 10.71).
In adjusted models, prediagnosis MVPA was associated with a 43% lower risk of 5-year all-cause mortality in a comparison of never/rare exercisers to women who reported more than 7 hours of MVPA per week (HR = 0.57, 95% CI = 0.33 to 0.98; Table 3 ). After further adjustment for BMI, the association was attenuated (HR = 0.64, 95% CI = 0.37 to 1.12). Prediagnosis MVPA was not related to endometrial cancer mortality. We found no association between MVPA and 10-year all-cause and endometrial cancerspecific mortality. Few cardiovascular deaths (n = 16 at 5 years, n = 30 at 10 years) precluded analysis of MVPA and CVD death.
We also assessed the joint effect of BMI and physical activity (Figure 1 ). Although the interaction term was not statistically significant (P interaction = .14), compared with women who were non-obese (BMI < 30 kg/m 2 m) and reported some activity (>1 hour/ week MVPA), we observed an increased risk of 5-year mortality for nonobese women who were inactive (HR = 2.28, 95% CI = 1.28 to 4.05) and obese women who reported some activity (HR = 1.70, 95% CI = 1.13 to 2.56) or were inactive (HR = 2.05, 95% CI = 1.11 to 3.77).
Discussion
In our study of women with endometrial cancer, higher prediagnosis BMI was associated with an increased risk of overall and endometrial cancer-specific 5-and 10-year mortality and an increased risk for 10-year CVD mortality. More MVPA was related to lower overall 5-year mortality but not disease-specific mortality or 10-year mortality. In joint effect analysis, even among nonobese women, those who were inactive had an increased risk of 5-year mortality compared with nonobese, active women.
BMI and physical activity may affect endometrial cancer survival through various pathways. Obesity may affect tumorigenesis and tumor progression through insulin resistance and hyperinsulinemia, increased bioavailability of steroid hormones, and localized inflammation (26) . In 11 randomized controlled trials among breast, prostate, gastric, and colorectal cancer survivors, associations between physical activity and biomarkers of the insulin pathway, inflammation, and cell-mediated immunity showed mixed results, reporting changes in the insulin pathway but not of a consistent magnitude (27) . Changes in the insulin pathway appeared to be strongest among obese and sedentary patients, and other studies also suggested that the beneficial effects of physical activity were more pronounced in overweight or obese individuals (28) . Still, our findings on joint effects of BMI and physical activity suggest that despite no multiplicative interaction, even those who are normal weight and inactive may be at increased mortality risk compared with those who are normal weight and active. Also, overweight and inactive individuals are more likely to develop diabetes (29) , and diabetics with cancer have higher overall mortality than nondiabetics with cancer (30) . Physical activity has been shown to be protective against diabetes (29) . Other suggested explanations for the association between BMI and mortality include surgical complications, tumor characteristics, or the role of menopausal hormone therapy. However, a recent study comparing surgical staging outcomes between nonobese and obese women showed that primary surgical treatment operative complications did not vary by BMI (31) . Although some studies have shown that higher BMI is associated with better endometrial tumor characteristics (9, 10, (12) (13) (14) 16, 17, 19) , our study does not support this association. Also, among those who never used menopausal hormone therapy, the magnitude of association between BMI and 5-year mortality was similar to that observed among all women, lessening the likelihood that our results were confounded by menopausal hormone therapy.
Evidence on physical activity and endometrial cancer survival is sparse. The only previous study on physical activity and endometrial cancer survival found no association between prediagnosis MVPA and all-cause or endometrial cancer-specific mortality in the WHI (20) . Different results may be explained by the specifics of the physical activity questionnaires, timing of MVPA assessment relative to diagnosis, health differences between populations, or differences in adjustment factors.
Strengths of our study include the prospective nature of the cohort and standardized mortality ascertainment. To our knowledge, this is the first prospective cohort to assess prediagnosis BMI, physical activity, and endometrial cancer survival with information on treatment and to assess joint effects of BMI and physical activity. We also stratified by various mortality risk factors, such as tumor characteristics, treatment, diabetes, and smoking, to explore possible effect modification. In addition, we were able to examine the effect of BMI on CVD mortality, an important cause of death among endometrial cancer survivors. This study is limited by few deaths among endometrial cancer patients, particularly in the subset of the population used for analysis of physical activity. The few deaths attributable to CVD in our study may also explain the lack of a statistically significant association between BMI and 5-year CVD mortality. Whereas in the SEER study of endometrial cancer patients, 40.6% of deaths 10 years after diagnosis were due to CVD (6), in our study, approximately 16% of deaths were attributable to CVD at 10 years in both the BMI and MVPA analytic cohorts. It is possible that because our study participants had more education than the general population (21), they may also have had better access to healthcare.
Other limitations of the study include that we had only selfreported, prediagnosis BMI and physical activity measures. Still validation studies have shown high correlations (r > 0.9), between self-report and measured BMI and self-reported BMI is widely accepted as a measure of adiposity in epidemiologic studies (32) . Although this MVPA questionnaire has been shown to have construct validity in cancer studies with other outcomes, measurement error may have resulted in attenuation of the risk estimates, and fewer deaths in the MVPA analysis could have limited our Cox proportional hazards models were used with age as the underlying time metric (age at diagnosis and age at death or censoring). Nonobese was defined as a body mass index less than 30 kg/m 2 , and active was defined as more than 1 hour/ week of moderate to vigorous physical activity. P interaction = .14 for obesity and physical activity. Models were adjusted for categorical variables of tumor grade, tumor stage, surgery, chemotherapy, race, family history of breast cancer, diabetes, and smoking status.
ability to detect statistically significant associations. Also, the time from baseline measures to cancer diagnosis was not uniform, and both BMI and MVPA may have changed over time (33, 34) . We did not assess BMI or physical activity after diagnosis and thus were not able to examine postdiagnosis measures and mortality. Although models accounted for age and we performed sensitivity analyses stratified by median age at diagnosis, the aging effect in a study of mortality cannot be eliminated. Another limitation is that we had information on tumor stage and grade and first course of treatment only as reported by cancer registries. However, stratification by cancer stage and grade did not show statistically significantly different results for those missing data, and additional sensitivity analyses to assess confounding by missing tumor characteristics and treatment did not change our observed associations.
In summary, in this study of women with endometrial cancer, prediagnosis BMI was related to an increased risk of 5-and 10-year all-cause and endometrial cancer-specific mortality and 10-year CVD mortality. We also observed a suggested protective association of physical activity with mortality. Future research is needed to understand the importance of both pre-and postdiagnosis obesity or physical activity and biological mechanisms underlying the observed association. 
